PALB2 and neoplasm: In a study of patients with tumor CGP-identified mutations in moderate risk breast and ovarian CSGs (ATM, BRIP1, CHEK2, PALB2, RAD51C, and RAD51D), 24% of patients with germline variants would not have met criteria for germline testing24.